AcuCort ABNGM: ACUC

AcuCort awarded funding from Region Skåne to support its US expansion

· Issued by AcuCort AB

Summary by 6ix AI

AcuCort, which sells Zeqmelit, a dexamethasone-based oral film placed on the tongue, has been awarded SEK 150,000 in funding from Region Skåne to accelerate its commercial activities in the United States. AcuCort will match the funding, giving a total project budget of at least SEK 300,000.

Key details

  • The project will include market and business analyses, identifying potential commercial partners, meetings and participation in life science events in the United States, with the aim of establishing a commercial partnership for Zeqmelit and laying the foundation for a future US launch.
  • The US Food and Drug Administration (FDA) has previously granted AcuCort a Small Business Waiver, which exempts it from the FDA application fee for its forthcoming New Drug Application, the filing that seeks US approval to market a drug.
  • AcuCort has reached agreement with the FDA on an initial Pediatric Study Plan, a plan for studies in children, meaning no additional studies need to be conducted before the New Drug Application is submitted.
  • Zeqmelit is approved and marketed in Sweden, Denmark, Norway and Finland.

What’s still pending

  • A commercial partnership for Zeqmelit in the US has not yet been established.
  • The New Drug Application has not yet been submitted to the FDA.

6ix AI wrote this summary from the release below and checked it against the release.

AcuCort has been awarded funding from Region Skåne to accelerate the company's commercial activities in the United States. The funding amounts to SEK 150,000 and will be matched by AcuCort, resulting in a total project budget of at least SEK 300,000.

"We have reached important regulatory milestones in our dialogue with the FDA and can now accelerate our commercial activities in the United States. Our focus is on identifying a strong commercial partner that can become involved at an early stage and contribute to a successful launch of Zeqmelit® in the US market," says Jonas Jönmark, CEO of AcuCort.

The FDA has previously granted AcuCort a Small Business Waiver, which exempts the company from the FDA's application fee for its forthcoming New Drug Application (NDA). AcuCort has also reached agreement with the FDA on an initial Pediatric Study Plan (iPSP), meaning that no additional studies need to be conducted before the NDA is submitted.

The project will include market and business analyses, the identification of potential commercial partners, meetings and participation in relevant life science events in the United States. The objective is to establish a commercial partnership for Zeqmelit® and lay the foundation for a future launch in the US market.

Region Skåne stated that the investment will contribute to sustainable growth and enhance the competitiveness of companies.

For further information: 
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: [email protected]

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

https://news.cision.com/acucort-ab/r/acucort-awarded-funding-from-region-skane-to-support-its-us-expansion,c4396430

https://mb.cision.com/Main/15601/4396430/4270966.pdf

(c) 2026 Cision. All rights reserved., source Press Releases - English

AcuCort AB on 6ix

Earlier from AcuCort

All AcuCort news releases